FDA approves GEs cardiovascular US system
The FDA has cleared the latest version of GE Healthcare’s Vivid E9 cardiovascular ultrasound system.
Dubbed the Vivid E9 Breakthrough 2012, the system includes a 4D transducer for transesophageal echocardiography and tools designed to improve workflow. Currently, Vivid E9 is used most frequently in the echo lab, but the additions in the latest version enable the system’s use in settings such as the cath lab or operating room, according to GE.
Other procedures supported by the addition of the 4D transducer are mitral valve repair, transcatheter aortic valve repair, atrial septal defect closures and patent foraman ovale closures.
Dubbed the Vivid E9 Breakthrough 2012, the system includes a 4D transducer for transesophageal echocardiography and tools designed to improve workflow. Currently, Vivid E9 is used most frequently in the echo lab, but the additions in the latest version enable the system’s use in settings such as the cath lab or operating room, according to GE.
Other procedures supported by the addition of the 4D transducer are mitral valve repair, transcatheter aortic valve repair, atrial septal defect closures and patent foraman ovale closures.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.